Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Inc.

Leading with purpose. Every day.“Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease. Our focus is on doing the right things for patients both during development and commercialization to deliver on the promise of these therapies in a way that's meaningful for rare disease communities.”Emil D. Kakkis, M.D., Ph.D.Chief Executive Officer and PresidentWe have an inclusive culture of value and respect.Ultragenyx brings novel products to those living with rare and ultrarare diseases with a focus on debilitating genetic diseases. Founded in 2010, we have rapidly built a diverse portfolio of approved therapies and products aimed at diseases with a high unmet medical need for which many have no approved therapies. It takes courage, care, talent, and dedication to make a meaningful impact for those living with rare diseases, their families and the rare disease community.  We put our people first, so they can take care of the rare disease community.We purposefully cultivate and nurture a dynamic, supportive work environment where we encourage every team member to share their new ideas and help us unlock more possibilities. Our team is made up of exceptional and diverse people with a strong passion and commitment to helping those living with rare diseases. By embracing generosity, curiosity, inclusion, and humility we are constantly learning together—fostering an environment that supports profound growth and fulfillment.If you want to have a meaningful impact, do the best work of your career while having fun and growing professionally and personally, come join our team!Visit our community guidelines at: https://ultragenyx.co/community

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue				133K -	2.61M 1,863.91%	51.49M 1,871.48%	103.71M 101.41%	271.03M 161.32%	351.41M 29.66%	363.33M 3.39%	434.25M 19.52%
cost of revenue					1K -	1.15M 114,500%	9.01M 686.04%	6.13M 31.96%	16.01M 161.18%	28.32M 76.91%	45.21M 59.64%
gross profit				133K -	2.61M 1,863.16%	50.35M 1,828.34%	94.71M 88.10%	264.90M 179.71%	335.40M 26.61%	335.01M 0.12%	389.04M 16.13%
selling and marketing expenses
general and administrative expenses	4.45M -	10.81M 142.89%	33.00M 205.25%	64.94M 96.77%	99.91M 53.86%	127.72M 27.84%
selling general and administrative expenses	4.45M -	10.81M 142.89%	33.00M 205.25%	64.94M 96.77%	99.91M 53.86%	127.72M 27.84%	161.52M 26.46%	182.93M 13.25%	219.98M 20.25%	278.14M 26.44%	309.80M 11.38%
research and development expenses	27.83M -	45.97M 65.18%	114.74M 149.61%	183.20M 59.67%	231.64M 26.44%	294.00M 26.92%	357.36M 21.55%	412.08M 15.32%	497.15M 20.64%	705.79M 41.97%	648.45M 8.12%
other expenses	-3.01M -	-3.02M 0.60%	-200K 93.39%	2.17M 1,184%	10.60M 389.11%	3.95M 62.71%	12.45M 214.90%	7.64M 38.60%	241K 96.85%	9.51M 3,845.23%	-337K 103.54%
cost and expenses	32.28M -	56.78M 75.89%	147.74M 160.20%	248.14M 67.96%	331.55M 33.62%	422.87M 27.54%	527.89M 24.83%	601.15M 13.88%	733.14M 21.96%	1.01B 38.07%	1.00B 0.87%
operating expenses	32.28M -	56.78M 75.89%	147.74M 160.20%	248.14M 67.96%	331.55M 33.62%	421.72M 27.20%	518.88M 23.04%	595.02M 14.67%	717.13M 20.52%	983.93M 37.20%	958.25M 2.61%
interest expense							1.14M -	33.29M 2,833.13%	29.42M 11.62%	43.02M 46.20%	66.00M 53.44%
ebitda	-34.63M -	-56.78M 63.98%	-146.35M 157.77%	-248.01M 69.46%	-328.94M 32.63%	-541.70M 64.68%	-411.72M 23.99%	-322.47M 21.68%	-381.50M 18.30%	-639.41M 67.61%	-516.85M 19.17%
operating income	-32.28M -	-56.78M 75.89%	-147.74M 160.20%	-248.01M 67.87%	-328.94M 32.63%	-371.37M 12.90%	-424.17M 14.22%	-330.12M 22.17%	-381.74M 15.64%	-648.92M 69.99%	-569.21M 12.28%
depreciation and amortization	444K -	684K 54.05%	1.38M 102.34%	3.42M 147.40%	5.83M 70.12%	19.54M 235.42%	12.45M 36.27%	7.64M 38.60%	241K 96.85%	9.51M 3,845.23%	26.01M 173.52%
total other income expenses net	-3.01M -	-3.02M 0.60%	-200K 93.39%	2.17M 1,184%	10.60M 389.11%	174.28M 1,543.49%	24.73M 85.81%	144.76M 485.37%	-71.24M 149.22%	-52.81M 25.88%	-39.26M 25.66%
income before tax	-35.07M -	-59.80M 70.52%	-145.62M 143.50%	-245.84M 68.82%	-318.34M 29.49%	-197.10M 38.09%	-399.44M 102.66%	-185.36M 53.60%	-452.98M 144.38%	-701.73M 54.91%	-608.46M 13.29%
income tax expense	-3.01M -	-684K 77.25%	-2.32M 239.18%	35K 101.51%	-16.20M 46,382.86%	514K 103.17%	3.28M 538.72%	1.21M 63.23%	1.04M 13.50%	5.70M 445.59%	-1.82M 132.04%
net income	-35.07M -	-59.80M 70.52%	-145.62M 143.50%	-245.87M 68.85%	-302.14M 22.88%	-197.61M 34.60%	-402.73M 103.80%	-186.57M 53.67%	-454.02M 143.36%	-707.42M 55.81%	-606.64M 14.25%
weighted average shs out	29.06M -	28.76M 1.05%	36.78M 27.91%	39.59M 7.62%	42.45M 7.24%	49.78M 17.25%	56.58M 13.66%	60.85M 7.54%	67.80M 11.42%	69.91M 3.13%	73.54M 5.19%
weighted average shs out dil	29.06M -	28.76M 1.05%	36.78M 27.91%	39.59M 7.62%	42.45M 7.24%	49.78M 17.25%	56.58M 13.66%	60.85M 7.54%	67.80M 11.42%	69.91M 3.13%	73.54M 5.19%
eps	-1.21 -	-2.08 71.90%	-3.96 90.38%	-6.21 56.82%	-7.12 14.65%	-3.97 44.24%	-7.12 79.35%	-3.07 56.88%	-6.70 118.24%	-10.12 51.04%	-8.25 18.48%
epsdiluted	-1.21 -	-2.08 71.90%	-3.96 90.38%	-6.21 56.82%	-7.12 14.65%	-3.97 44.24%	-7.12 79.35%	-3.07 56.88%	-6.70 118.24%	-10.12 51.04%	-8.25 18.48%

COM:ULTRAGENYX

Ultragenyx Pharmaceutical Inc.

Last Close

50.73

12/11 20:20

Market Cap

3.85B

Beta: -

Volume Today

458.34K

Avg: -

Preview